HOME >> BIOLOGY >> NEWS
New study suggests promising drug combinations for sleeping sickness

Results from a clinical trial evaluating new drug combinations for sleeping sickness, carried out by the international humanitarian medical aid agency Medecins Sans Frontieres (MSF), and its research arm, Epicentre, have now been published in the journal PLoS Clinical Trials.

African trypanosomiasis, or sleeping sickness affects many tens of thousands of people each year in sub-Saharan Africa and is a serious disease for which there are few treatment options. The most commonly used drug, Melarsoprol, is highly toxic. MSF and Epicentre jointly carried out a trial that started in 2001 in Uganda to evaluate the efficacy and safety of three drug combinations for this disease. The aim was to find out if any of these combinations would provide a viable treatment option for patients with second-stage sleeping sickness, where infection has reached the brain and prognosis is normally very poor. In the trial the drug combinations compared were melarsoprol-nifurtimox, melarsoprol-eflornithine, and nifurtimox-eflornithine. However, once 54 patients had been recruited (435 were planned), it was obvious that the death rate was much higher amongst individuals receiving one of the combinations, so the trial was stopped.

In the trial, the cure rate for nifurtimox-eflornithine was over twice that for melarsoprol-nifurtimox and substantially higher than that for melarsoprol-eflornithine. The rates of adverse events were also lower for patients treated with nifurtimox-eflornithine. These findings are encouraging and suggest that the nifurtimox-eflornithine combination has potential as a future therapy for second-stage African trypanosomiasis, and should be evaluated further in clinical trials.


'"/>

Contact: Sarah Clark
sclark@plos.org
Public Library of Science
8-Dec-2006


Page: 1

Related biology news :

1. New study warns limited carbon market puts 20 percent of tropical forest at risk
2. Clones on task serve greater good, evolutionary study shows
3. Pollution causes 40 percent of deaths worldwide, study finds
4. A study by the MUHC and McGill University opens a new door to understanding cancer
5. New study suggests Concord grape juice may provide protection against breast cancer
6. Preclinical study links gene to brain aneurysm formation
7. In limiting life span, study finds booming bacteria innocent
8. Multicenter study nets new lung tumor-suppressor gene
9. MIT study: Maturity brings richer memories
10. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study
11. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2019)... ... ... Gateway Genomics , a leading developer of direct-to-consumer genetic tests that ... Inc. 500|5000 list of fastest growing private companies, in the first year the ... generating revenue by March 31, 2015. Ranking in the list is determined by the ...
(Date:8/6/2019)... ... August 06, 2019 , ... ... manufacturing with clinical, regulatory and GMP manufacturing experience. In November it spun ... With extensive regulatory experience and one of the first cGMP cell ...
(Date:8/4/2019)... , ... August 02, 2019 , ... ... the life science industry in advancing the development of medical therapies, announced today ... by PharmaVOICE magazine as one of the “100 Most Inspiring People in the ...
Breaking Biology News(10 mins):
(Date:7/17/2019)... ... July 16, 2019 , ... ... manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal ... have dedicated manufacturing space at the new, state-of-the-art commercial manufacturing center near ...
(Date:7/2/2019)... ... ... Leading Regenerative Veterinary Medicine company, VetStem Biopharma , was recently featured ... focuses on regenerative veterinary medicine as a means of improving the quality of life ... the Brentwood and Pacific Palisades International Film Festival in Los Angeles, California where it ...
(Date:6/11/2019)... ... June 10, 2019 , ... Thought Technology Ltd ... appointment of Biofeedback Tech Ltd as its authorised distributor for the ... of many therapeutic treatments and clinical assessment protocols to treat stress related disorders ...
(Date:6/11/2019)... ... June 11, 2019 , ... A study released ... cells (MSC-EV) are able to incorporate into human CD34+ cells, modifying their gene ... MSC-EVs also increased the cells’ ability to lodge into bone marrow. This research ...
Breaking Biology Technology:
Cached News: